1 week ago
Merck & Company (MRK) Stock Soars 12% Following Breakthrough Melanoma Trial Results
Merck (MRK) stock surged 12.12% after positive Phase 3 melanoma trial results with Moderna showed improved survival rates for intismeran plus KEYTRUDA.
The post Merck & Company (MRK) Stock Soars 12% Following Breakthrough Melanoma Trial Results appeared first on Blockonomi.
Source: Blockonomi →Related News
- 9 hours ago
The Trade Desk, Inc. (TTD) Stock: New Zuma Platform Brings Smarter AI, Simpler M...
- 9 hours ago
Laser Photonics Corporation (LASE) Stock: SOCOM Engagement Puts Counter-Drone Sy...
- 12 hours ago
Amazon (AMZN) Stock: Expands Nvidia Partnership as AI Demand Grows
- 12 hours ago
Marvell Technology (MRVL) Q2 Earnings Preview: Should Investors Buy Before Thurs...
- 12 hours ago
Nvidia (NVDA), Salesforce (CRM), CrowdStrike (CRWD), and Okta (OKTA) Soar as AI...